| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6696084 | SKYEPHARMA AG | Spray drying process and compositions of fenofibrate |
Sep, 2021
(2 years ago) | |
Triglide is owned by Skyepharma Ag.
Triglide contains Fenofibrate.
Triglide has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Triglide are:
- US6696084
Triglide was authorised for market use on 07 May, 2005.
Triglide is available in tablet;oral dosage forms.
Triglide can be used as a method of treating dyslipidemia and dyslipoproteinemia using a dosage form that can provide an effective amount of fenofibrate to a patient in a fasted state which is at least 90% of the auc amount provided by the dosage form.
The generics of Triglide are possible to be released after 11 September, 2021.
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 07 May, 2005
Treatment: A method of treating dyslipidemia and dyslipoproteinemia using a dosage form that can provide an effective amount of fenofibrate to a patient in a fasted state which is at least 90% of the auc amount ...
Dosage: TABLET;ORAL
TRIGLIDE family patents
